Compare GTEC & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GTEC | MRKR |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | 345 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7M | 16.6M |
| IPO Year | N/A | N/A |
| Metric | GTEC | MRKR |
|---|---|---|
| Price | $1.05 | $1.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.17 |
| AVG Volume (30 Days) | 192.8K | ★ 330.4K |
| Earning Date | 11-07-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.92 | N/A |
| Revenue | ★ $86,168,664.00 | $4,694,988.00 |
| Revenue This Year | $5.64 | N/A |
| Revenue Next Year | $3.93 | N/A |
| P/E Ratio | $1.11 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.92 | $0.81 |
| 52 Week High | $2.92 | $5.95 |
| Indicator | GTEC | MRKR |
|---|---|---|
| Relative Strength Index (RSI) | 46.23 | 67.32 |
| Support Level | $0.99 | $1.40 |
| Resistance Level | $1.17 | $1.49 |
| Average True Range (ATR) | 0.07 | 0.10 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 52.00 | 95.45 |
Greenland Technologies Holding Corp is a developer of quality solutions in the material handling industry. It is a transmission and drivetrain systems provider for material handling equipment such as forklift trucks for industrial and logistic applications. Geographically, the company has its presence in Domestic and International markets and earns majority of the revenue from Domestic Sales.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.